Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Filgrastim 5Ifosfamide 3Docetaxel 3Carboplatin 3belinostat 2Sunitinib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Etoposide 2Epirubicin 2Doxorubicin 2toripalimab 1temsirolimus 1tanespimycin 1resiquimod 1poly ICLC 1perifosine 1pegfilgrastim 1pazopanib 1liposomal doxorubicin 1ivosidenib 1etoposide phosphate 1enasidenib 1apatinib 1angiotensin I (1-7) 1alanosine 1Vincristine 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chondrosarcoma × alanosine × Clear all
NCT00062283 2013-06-26

Alanosine in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡